Ann H. Partridge
Ann Partridge led the POSITIVE trial showing women can safely pause hormone therapy to have a baby.
Directs Dana-Farber's adult survivorship and young-women's breast cancer programmes; principal investigator of the POSITIVE trial and the Young Women's Breast Cancer Study.
| Title | Journal | Year |
|---|---|---|
| Interrupting endocrine therapy to attempt pregnancy after breast cancer | New England Journal of Medicine | 2023 |
Pages like this
not linked directly; found by shared links- PersonNancy U. Lin
Shares Breast Cancer Research Foundation, Dana-Farber Brigham Cancer Center.
- IdeaRotate between drugs on a fixed schedule instead of waiting for failure
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- PersonWendy Parulekar
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- IdeaHormone tablets instead of surgery for small breast cancers in the frail over-80s
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- InstitutionBarbara Ann Karmanos Cancer Institute
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- IdeaCardiometabolic screening and treatment for survivors on long-term hormone therapy
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- ProductGoserelin / leuprolide (ovarian function suppression)
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- IdeaLow-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.